Bone status in men with heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure.
Bone status
Co-morbidities
Heart failure
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
revised:
01
02
2023
received:
20
07
2022
accepted:
01
02
2023
medline:
19
6
2023
pubmed:
14
2
2023
entrez:
13
2
2023
Statut:
ppublish
Résumé
To assess bone status expressed as hip bone mineral density (BMD) in men with heart failure (HF). A total of 141 male patients with HF underwent dual energy X-ray absorptiometry to assess their BMD. We analysed markers of bone metabolism. Patients were classified as lower versus higher BMD according to the median hip BMD (median = 1.162 g/cm Patients with HF lose BMD over time. Markers of bone turnover can help in identifying patients at risk with osteocalcin being an independent marker of lower hip BMD and osteoprotegerin an independent predictor of death. HF patients with increased osteocalcin and osteoprotegerin may benefit from BMD assessment as manifest osteoporosis seems to be too late for clinically meaningful intervention in HF.
Substances chimiques
Osteoprotegerin
0
Osteocalcin
104982-03-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
714-723Subventions
Organisme : FP7/2007-2013 Ideas: European Research Council
ID : 241558
Informations de copyright
© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24:4-131.
Seferović PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinković I, et al. The Heart Failure Association atlas: heart failure epidemiology and management statistics 2019. Eur J Heart Fail. 2021;23:906-14.
Labrosciano C, Horton D, Air T, Tavella R, Beltrame JF, Zeitz CJ, et al. Frequency, trends and institutional variation in 30-day all-cause mortality and unplanned readmissions following hospitalisation for heart failure in Australia and New Zealand. Eur J Heart Fail. 2021;23:31-40.
Piepoli MF, Adamo M, Barison A, Bestetti RB, Biegus J, Böhm M. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. Eur J Heart Fail. 2022;24:143-68.
Tomasoni D, Adamo M, Metra M. March 2022 at a glance: focus on medical therapy, prevention and comorbidities. Eur J Heart Fail. 2022;24:403-5.
Tomasoni D, Adamo M, Metra M. November 2022 at a glance: focus on epidemiology, prognosis and comorbidities. Eur J Heart Fail. 2022;24:1997-9.
Canepa M, Ameri P, Lainscak M. Chronic obstructive pulmonary disease and comorbidities in heart failure: the next frontier of sodium-glucose co-transporter 2 inhibitors? Eur J Heart Fail. 2021;23:644-7.
von Haehling S, Arzt M, Doehner W, Edelmann F, Evertz R, Ebner N, et al. Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials. Eur J Heart Fail. 2021;23:92-113.
Bielecka-Dabrowa A, Ebner N, Dos Santos MR, Ishida J, Hasenfuss G, von Haehling S. Cachexia, muscle wasting, and frailty in cardiovascular disease. Eur J Heart Fail. 2020;22:2314-26.
Emami A, Saitoh M, Valentova M, Sandek A, Evertz R, Ebner N, et al. Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur J Heart Fail. 2018;20:1580-7.
Hajahmadi M, Shemshadi S, Khalilipur E, Amin A, Taghavi S, Maleki M, et al. Muscle wasting in young patients with dilated cardiomyopathy. J Cachexia Sarcopenia Muscle. 2017;8:542-8.
Carbone S, daSilva-deAbreu A, Lavie CJ. Weighing in on weight loss in heart failure with reduced ejection fraction. Eur J Heart Fail. 2023;25:128-30.
Anker SD, Khan MS, Butler J, Ofstad AP, Peil B, Pfarr E, et al. Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced. Eur J Heart Fail. 2023;25:117-27.
von Haehling S, Ebner N, Dos Santos MR, Springer J, Anker SD. Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat Rev Cardiol. 2017;14:323-41.
Carbone L, Buzkova P, Fink HA, Lee JS, Chen Z, Ahmed A, et al. Hip fractures and heart failure: findings from the Cardiovascular Health Study. Eur Heart J. 2010;31:77-84.
Loncar G, Cvetinovic N, Lainscak M, Isaković A, von Haehling S. Bone in heart failure. J Cachexia Sarcopenia Muscle. 2020;11:381-93.
Bozic B, Loncar G, Prodanovic N, Radojicic Z, Cvorovic V, Dimkovic S, et al. Relationship between high circulating adiponectin with bone mineral density and bone metabolism in elderly males with chronic heart failure. J Card Fail. 2010;16:301-7.
Martens P, Ter Maaten JM, Vanhaen D, Heeren E, Caers T, Bovens B, et al. Heart failure is associated with accelerated age related metabolic bone disease. Acta Cardiol. 2021;76:718-26.
Katano S, Yano T, Tsukada T, Kouzu H, Honma S, Inoue T, et al. Clinical risk factors and prognostic impact of osteoporosis in patients with chronic heart failure. Circ J. 2020;84:2224-34.
Fülster S, Tacke M, Sandek A, Ebner N, Tschöpe C, Doehner W, et al. Muscle wasting in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur Heart J. 2013;34:512-9.
von Haehling S, Lainscak M, Doehner W, Ponikowski P, Rosano G, Jordan J, et al. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle. 2010;1:187-94.
Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, et al. Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc. 2011;12:403-9.
Bruce RA, Blackmon JR, Jones JW, Strait G. Exercise testing in adult normal subjects and cardiac patients. Pediatrics. 1963;32:742-56.
Jankowska EA, Jakubaszko J, Cwynar A, Majda J, Ponikowska B, Kustrzycka-Kratochwil D, et al. Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants. Eur J Heart Fail. 2009;11:28-38.
Kenny AM, Boxer R, Walsh S, Hager WD, Raisz LG. Femoral bone mineral density in patients with heart failure. Osteoporos Int. 2006;17:1420-7.
Majumdar SR, Ezekowitz JA, LM, Leslie WD. Heart failure is a clinically and densitometrically independent risk factor for osteoporotic fractures: population-based cohort study of 45,509 subjects. J Clin Endocrinol Metab. 2012;97:1179-86.
Iwaniec UT, Turner RT. Influence of body weight on bone mass, architecture and turnover. J Endocrinol. 2016;230:R115-30.
Zengin A, Pye SR, Cook MJ, Adams JE, Rawer R, Wu FCW, et al. Associations of muscle force, power, cross-sectional muscle area and bone geometry in older UK men. J Cachexia Sarcopenia Muscle. 2017;8:598-606.
Loncar G, Springer J, Anker M, Doehner W, Lainscak M. Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle. 2016;7:246-60.
Loncar G, Fülster S, von Haehling S, Popovic V. Metabolism and the heart: an overview of muscle, fat, and bone metabolism in heart failure. Int J Cardiol. 2013;162:77-85.
Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997;103:197-207.
Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol. 2004;287:H2023-6.
Lim LS, Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Ensrud KE; Osteoporotic Fractures in Men (MrOS) Study Group. Loop diuretic use and increasedrates of hip bone loss in older men: the Osteoporotic Fractures in Men study. Arch Intern Med. 2008;168:735-40.
Youn JC, Lee SJ, Lee HS, Oh J, Hong N, Park S, et al. Exercise capacity independently predicts bone mineral density and proximal femoral geometry in patients with acute decompensated heart failure. Osteoporos Int. 2015;26:2121-9.
Terrovitis J, Zotos P, Kaldara E, Diakos N, Tseliou E, Vakrou S, et al. Bone mass loss in chronic heart failure is associated with secondary hyperparathyroidism and has prognostic significance. Eur J Heart Fail. 2012;14:326-32.
von Haehling S. The wasting continuum in heart failure: from sarcopenia to cachexia. Proc Nutr Soc. 2015;74:367-77.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891-975.
Zão A, Magalhães S, Santos M. Frailty in cardiovascular disease: screening tools. Rev Port Cardiol. 2019;38:143-58.
Uchmanowicz I, Młynarska A, Lisiak M, Kałużna-Oleksy M, Wleklik M, Chudiak A, et al. Heart failure and problems with frailty syndrome: why it is time to care about frailty syndrome in heart failure. Card Fail Rev. 2019;5:37-43.
Loncar G, Bozic B, Cvorovic V, Radojicic Z, Dimkovic S, Markovic N, et al. Relationship between RANKL and neuroendocrine activation in elderly males with heart failure. Endocrine. 2010;37:148-56.
Roysland R, Masson S, Omland T, Milani V, Bjerre M, Flyvbjerg A, et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial. Am Heart J. 2010;160:286-93.